Table 3 Studies, in which classical cerebrospinal fluid (CSF) biomarkers were evaluated, are enlisted; if reported, values of Beta-Amyloid 42 (Ab42), Alpha-Synuclein (a-syn), Total-Tau (T-Tau), Phospho-Tau (P-Tau), Neurofilament Light Chains (NfL) and the detection method are described
References | Subgroups | CSF Ab42 pg/ml mean (*) | CSF a-syn pg/ml mean (*) | CSF T-Tau pg/ml mean (*) | CSF P-Tau pg/ml mean (*) | CSF NfL pg/ml mean (*) | Methods |
|---|---|---|---|---|---|---|---|
Olssonn et al. [31] |  | 255 [166–293] | N | 71 [62–108] | 21 [16–28] | 1281 [828–2713] | Luminex: Ab42 + T-Tau + P-Tau ELISA: NfL |
Magdalinou et al. [36] |  | 715 (553–878) | 1497 (1183–1811) | 286 [234–381] | 38 [30–45] | 1937 [1465–3434] | Fujirebio: Ab42 + T-Tau + P-Tau ELISA: NfL + a-syn |
Hansson et al. [27] | Lund cohort | 538 (288) | N | 358 (93) | 58.3 (18.4) | 2.498 (848) | Fujirebio: Ab42 + T-Tau + P-Tau ELISA: CSF NfL |
London cohort | 745 (295) | N | 425 (289) | 47.3 (21) | 2.845 (2.269) | ||
Hall et al. [28] |  | 380 [234.5–611.1] | N | 420.8 [219.8–661.4] | 39.9 [24.8–54.8] | N | ELISA: Ab42 + T-Tau + P-Tau |
Aerts et al. [15] |  | 730 (316) | N | 402 (199) | 48 [38–59] | N | ELISA: Ab42 + T-Tau + P-Tau |
Benvenutto et al. [33] | CBS-A +  | 361 [307–397] | N | 593 [348–809] | 83 [65–123] | N | ELISA: Ab42 + T-Tau + P-Tau |
CBS-A- | 843 [521.25–1140.75] | N | 279.5 [193.75–3479.25] | 45.5 [33.5–61.5] | N | ||
Meeter et al. [24] |  | 810 [607–999] | N | 336 [246–446] | 47 [38–57] | 2664 [1715–4158] | Fujirebio: Ab42 + T-Tau + P-Tau ELISA: NfL |
Alcolea et al. [29] |  | 480.1 (165.3) | N | 279.5 (108) | 43.4 (13.3) | 2,264.3 (1216.5) | ELISA: Ab42 + T-Tau + P-Tau + NfL |
Borroni et al. [26] | CBS | 748.2 (431.5) | N | 409.1 (285.3) | N | N | ELISA: Ab42 + T-Tau |
CBS nAD-like | 865.2 (402.5) | N | 337.7 (242.5) | N | N | ||
CBS AD-like | 280.2 (77.3) | N | 694.7 (281.7) | N | N | ||
SPECT- nAD-like | 888.9 (412.5) | N | 308.1 (223.1) | N | N | ||
SPECT- AD-like | 266.1 (77.2) | N | 726.5 (302.7) | N | N | ||
Boman et al. [22] | CBS + PSP patients | N | N | N | N | N | Western blot |
Delaby et al. [25] |  | 696 [479–911] | N | 302 [209–424] | 51 [40–64] | 1637 [923–2797] | Fujirebio: Ab42 + T-Tau + P-Tau ELISA: NfL |
Quadalti et al. [20] | CBS + PSP patients | 655 [476.3–877.0] | N | 195 [157.3–282.3] | 29 [22.3–37.8] | 1569 [1120–2128] | Fujirebio: Ab42 + T-Tau + P-Tau Quanterix: NfL |
Rodriguez et al. [52] | CBS + PSP patients | 524.6 (193.4) | N | 244.8 (112.6) | 41.2 (15) | N | Fujirebio: Ab42 + T-Tau + P-Tau |
Schulz et al. [30] |  | N | 714.87 (179.91) | 70.58 (39.06) | N | 4595.31 (3635.94) | ELISA: a-syn Quanterix: T-Tau + P-Tau + NfL |
Di Stefano F et al. [51] | CBS | N | N | N | N | N | Fujirebio: Ab42 + T-Tau + P-Tau |
CBS AD +  | 288 (97) | N | 655 (324) | 113 (63) | N | ||
CBS AD - | 573 (212) | N | 317 (157) | 46 (19) | N |